###### Practice points

-   Prolonged levodopa use in advanced Parkinson\'s disease patients is associated with motor complications including motor response fluctuations and levodopa-induced dyskinesia.

-   This was a *Post hoc* analysis of GLORIA, a 24-month observational registry that evaluated long-term effectiveness of levodopa--carbidopa intestinal gel (LCIG) in a real-world setting.

-   Patients were divided into subgroups based on self-reported \<4 (low) and ≥4 (high) h/day of baseline dyskinesia.

-   Mean duration of dyskinesia improved in patients with high dyskinesia burden at baseline and increased in patients with low dyskinesia burden at baseline.

-   At the same time, dyskinesia severity and pain associated with dyskinesia improved to a greater extent in patients with high versus low baseline dyskinesia, with numerical improvements in the low dyskinesia burden group.

-   LCIG treatment markedly improved quality of life in patients with low and high baseline dyskinesia.

-   Adverse drug reactions occurred at a similar rate in both subgroups.

-   Despite increases in levodopa dose, LCIG treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson\'s disease patients and high dyskinesia burden at baseline.

Levodopa is the most effective treatment for Parkinson\'s disease (PD), but prolonged use in patients is associated with motor complications including motor and nonmotor response fluctuations and a range of levodopa-induced dyskinesias \[[@B1]\]. Motor complications are thought to be caused by fluctuating levodopa blood levels due to irregular gastric emptying and intestinal levodopa absorption (delayed 'On' and no 'On'), the short half-life of levodopa and resulting maladaptive neuroplasticity \[[@B5],[@B6]\]. Motor and nonmotor complications have been shown to negatively impact quality of life (QoL) in patients with advanced PD.

Levodopa--carbidopa intestinal gel (LCIG, designated in the USA as carbidopa-levodopa enteral suspension \[CLES\]; Duopa^®^/Duodopa^®^, AbbVie Inc., IL, USA) is delivered continuously via percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG-J) and is a long-term treatment option for motor fluctuations in patients with advanced PD who are refractory to oral medication. LCIG has been shown to reduce motor and nonmotor complications and improve QoL in patients with advanced PD \[[@B7]\].

The GLORIA registry \[[@B11],[@B12]\] evaluated the long-term efficacy and safety of LCIG in routine care of patients with advanced PD. This *post hoc* analysis of the GLORIA registry evaluated the long-term effect of LCIG on dyskinesia burden (dyskinesia duration and severity) in subgroups of patients.

Methods {#S0001}
=======

Study design & treatment {#S0002}
------------------------

GLORIA is a multinational observational registry designed to collect efficacy and safety data of routine clinical care use of LCIG over 24 months. This registry has been described previously in more detail \[[@B11],[@B12]\]. GLORIA was conducted according to Good Clinical Practice Guidelines and Institutional Review Board requirements, as applicable.

Patients were individually titrated to LCIG via nasojejunal (NJ) tube. After PEG-J placement, patients were treated for up to 24 months with LCIG. Concomitant PD medications were allowed at the discretion of the investigator.

Patients {#S0003}
--------

Patients were enrolled in the registry according to the European Summary of Product Characteristics (having advanced levodopa-responsive PD with persistent severe motor fluctuations with or without troublesome dyskinesia) and national reimbursement criteria, where applicable. Patients were either LCIG naive or had received LCIG for a maximum of 12 months before enrollment. Observations were prospective for LCIG-naive patients and were partially retrospective and prospective for patients with previous LCIG experience.

Assessments {#S0004}
-----------

### Efficacy assessment {#S0005}

Efficacy outcomes described in this analysis include the mean change from baseline to study visit as evaluated by the Unified Parkinson\'s Disease Rating Scale (UPDRS) Part IV (complications of therapy including dyskinesia); items 32 and 39 were modified using the rating instructions for the corresponding parts 4.3 and 4.1 of the Movement Disorder Society (MDS)-UPDRS to allow for collection of actual hours of 'Off' time and 'On' time with dyskinesia as reported by the patient for the week prior to the clinical visit. UPDRS Part II (activities of daily living) and Part III (motor examination) were also assessed (in the 'On' state). Patient QoL was assessed via the 8-item Parkinson\'s Disease Questionnaire (PDQ-8). Efficacy was assessed at baseline before the initiation of LCIG via NJ tube; at discharge from hospital following PEG-J placement (day 1); and at 6, 12, 18 and 24 months after PEG-J placement.

### Safety assessment {#S0006}

Adverse drug reactions (ADRs) included all adverse events that had a reasonable possibility of being related to the treatment drug or device (as determined by the investigator). ADRs were recorded for the duration of the registry study and for 28 days after the patient\'s last visit.

Statistical analysis {#S0007}
--------------------

For this posthoc analysis, patients were allocated into two subgroups based on baseline hours/day of dyskinesia defined as low (\<4 h/day) and high (≥4 h/day). Patients without baseline dyskinesia assessment were excluded from the analysis. Statistical significance in the change from baseline to each time point for each efficacy measure was evaluated using a paired *t*-test.

Results {#S0008}
=======

Patients {#S0009}
--------

Out of 375 patients in the GLORIA registry, there were 118 patients (31%) with \<4 h/day of dyskinesia at baseline and 139 patients (37%) with ≥4 h/day dyskinesia at baseline (118 patients \[31%\] did not have measurements of dyskinesia duration at baseline). Overall, 258 patients (69%) completed the registry; cumulative withdrawals were higher in patients with high versus low baseline dyskinesia (51 \[37%\] vs 36 \[31%\] patients). The most prominent reasons for withdrawal were ADRs (n = 46; 12.3%), withdrawal of informed consent (n = 31; 8.3%), patients lost to follow-up (n = 16; 4.3%) and lack of efficacy (n = 11; 2.9%). Demographics were similar across the subgroups ([Table 1](#T1){ref-type="table"}). Patients with \<4 h/day of dyskinesia at baseline had slightly shorter PD duration, a slightly higher total daily levodopa dose, a slightly higher daily 'Off' time and fewer hours per day of dyskinesia. Activities of daily living, motor symptoms and QoL were similar in both subgroups.

###### **Baseline demographics and characteristics.**

  ---------------------------------------------------------------------------------------------------------------------
  **Characteristic**                                                **Baseline dyskinesia subgroup**   
  ----------------------------------------------------------------- ---------------------------------- ----------------
  Age, mean (SD)                                                    66.4 (8.1)                         64.9 (9.7)

                                                                                                       

  Sex, n (%):\                                                      \                                  \
  -- Female\                                                        41 (35)\                           71 (51)\
  -- Male                                                           77 (65)                            68 (49)

                                                                                                       

  Years since PD diagnosis, mean (SD)                               11.9 (6.5)                         13.3 (6.4)

                                                                                                       

  Total daily levodopa dose (mg), mean (SD)                         998.7 (450.1)                      859.7 (447.4)

                                                                                                       

  Hours/day of 'Off' time (UPDRS IV: modified item 39), mean (SD)   6.4 (3.5)^†^                       5.8 (2.9)^†^

                                                                                                       

  Hours/day of dyskinesia (UPDRS IV: modified item 32), mean (SD)   1.0 (1.2)^†^                       7.1 (2.8)^†^

                                                                                                       

  Activities of daily living (UPDRS II) 'On', mean (SD)             16.6 (8.9)^†^                      16.3 (10.9)^†^

                                                                                                       

  Motor examination (UPDRS III) 'On', mean (SD)                     25.0 (12.5)^†^                     23.4 (11.6)^†^

                                                                                                       

  Quality of life (PDQ-8), mean (SD)                                44.6 (19.1)^†^                     48.4 (19.2)^†^
  ---------------------------------------------------------------------------------------------------------------------

^†^Population with at least one post baseline efficacy assessment (\<4 h/day, n = 100; ≥4 h/day, n = 117).

PDQ-8: 8-item Parkinson\'s Disease Questionnaire; SD: Standard deviation; UPDRS: Unified Parkinson\'s Disease Rating Scale.

During 24 months of treatment, patients on LCIG monotherapy (e.g., no adjunctive therapy during the 16 h of LCIG infusion) had similar increases in levodopa-equivalent doses (LEDs), regardless of baseline dyskinesia ([Table 2](#T2){ref-type="table"}). The LEDs for patients on LCIG polytherapy (LCIG and ≥1 other anti-PD drug) were generally stable over 24 months with LEDs starting and ending at 2191.5 (846.1) mg/day and 2214.5 (840.3) mg/day, respectively, for patients with \<4 h/day baseline dyskinesia, and starting and ending at 1787.1 (793.8) mg/day and 1787.6 (769.7) mg/day, respectively, for patients with ≥4 h/day baseline dyskinesia.

###### **Levodopa-equivalent doses by treatment group and visit.**

  **Visit**   **\<4 h/day**   **≥4 h/day**                                                      
  ----------- --------------- ---------------- ---- ---------------- ---- ---------------- ---- ----------------
  Day 1       30              1658.3 (678.4)   77   2191.5 (846.1)   58   1381.3 (651.4)   70   1787.1 (793.8)
                                                                                                
  Month 6     32              1678.7 (574.6)   65   2201.3 (889.2)   58   1614.2 (821.9)   58   1747.0 (726.0)
                                                                                                
  Month 12    32              1945.2 (721.1)   61   2223.5 (837.8)   49   1674.0 (874.4)   57   1776.5 (829.3)
                                                                                                
  Month 18    22              1895.6 (744.0)   63   2119.7 (805.9)   46   1669.9 (884.7)   50   1841.9 (737.1)
                                                                                                
  Month 24    25              1680.9 (647.7)   56   2214.5 (840.3)   41   1625.7 (844.5)   48   1787.6 (769.7)

LCIG: Levodopa--carbidopa intestinal gel; SD: Standard deviation.

Efficacy {#S0010}
--------

### 'Off''time {#S0011}

Mean 'Off' time significantly decreased and remained stable for the study duration in both high and low baseline dyskinesia subgroups (p \< 0.0001 for both groups) ([Figure 1](#F0001){ref-type="fig"}A). By month 24, the mean (standard deviation \[SD\]) 'Off' time reduced by 3.9 (3.4) h in patients with high baseline dyskinesia and reduced by 4.4 (3.6) h in patients with low baseline dyskinesia (p \< 0.0001 for both).

![**Motor, nonmotor, and quality-of-life outcomes in patients with ≥4 and \<4 h/day baseline dyskinesia after 24 months of LCIG treatment.**\
Statistics indicate improvement from baseline. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.\
BL: Baseline; LCIG: Levodopa--carbidopa intestinal gel; PDQ 8: 8-item Parkinson\'s Disease Questionnaire; SD: Standard deviation; UPDRS: Unified Parkinson\'s Disease Rating Scale.](nmt-09-39-g1){#F0001}

### Dyskinesia {#S0012}

In patients with high baseline dyskinesia, the mean (SD) duration of dyskinesia decreased and remained stable through month 24 (reduction of 3.5 \[4.6\] h; p \< 0.0001; [Figure 1](#F0001){ref-type="fig"}B). In patients with low baseline dyskinesia, however, the mean duration of dyskinesia increased and maintained that increase through 24 months of treatment (+1.6 \[3.3\] h; p \< 0.0001).

Dyskinesia severity (UPDRS item 33) improved significantly over 24 months of treatment in patients with ≥4 h baseline dyskinesia (p \< 0.0001 for all time points; [Figure 1](#F0001){ref-type="fig"}C). In patients with low baseline dyskinesia, the severity of dyskinesia numerically improved with statistical significance at month 12 (p \< 0.05). Pain associated with dyskinesia (UPDRS item 34) also improved numerically with statistical significance at day 1 (p \< 0.05) in patients who had low and high baseline dyskinesia, but was only reduced in patients who had high baseline dyskinesia duration through month 24 (p \< 0.0001 for all time points) ([Figure 1](#F0001){ref-type="fig"}D).

### Other motor symptoms {#S0013}

Motor scores (UPDRS Part III) decreased from baseline, regardless of baseline dyskinesia. More specifically, after initiation of LCIG, patients experienced significant (p \< 0.0001) reductions from baseline in UPDRS Part III mean (SD) scores of -4.3 (8.7) and -4.5 (7.4) in patients with \<4 h/day and ≥4 h/day baseline dyskinesia, respectively. After 24 months, patients with low and high baseline dyskinesia had reductions from baseline in UPDRS Part III mean scores of -1.6 (10.8) and -2.9 (12.8), respectively, although these reductions were not statistically significant.

### Activities of daily living & QoL {#S0014}

The ability to perform activities of daily living, as measured by UPDRS Part II, improved in both patient subgroups ([Figure 1](#F0001){ref-type="fig"}E). Through month 18, patients with high baseline dyskinesia experienced significant (p \< 0.05) improvements from baseline; by month 24, scores were still numerically, but not significantly, reduced from baseline in both subgroups.

LCIG treatment led to significant improvements in QoL in both dyskinesia subgroups, although improvements were greater in patients with high baseline dyskinesia ([Figure 1](#F0001){ref-type="fig"}F). After LCIG initiation, PDQ-8 scores were significantly (p \< 0.05 for all) reduced from baseline until month 12 for patients with low baseline dyskinesia and until month 24 (p \< 0.01 for all) for patients with high baseline dyskinesia.

Safety {#S0015}
------

Overall, the proportion of patients experiencing ADRs was similar in both the high and low baseline dyskinesia subgroups ([Table 3](#T3){ref-type="table"}). Serious ADRs occurred slightly more frequently in the low versus high baseline dyskinesia duration subgroup (28.2 vs 22.3%, respectively), although fewer patients with low baseline dyskinesia experienced severe ADRs (12.7 vs 16.9%, respectively). The most common ADR leading to LCIG discontinuation that occurred in two patients was device dislocation; all other ADRs leading to discontinuation occurred in one patient each. ADRs leading to LCIG discontinuation were reported by more patients with high baseline dyskinesia than by patients with low baseline dyskinesia. The most commonly reported nondevice-related ADRs (occurring in ≥3% of patients in either group) were decreased weight, polyneuropathy, Parkinsonism, dyskinesia, psychotic disorder, depression, abdominal pain, hallucination and fall.

###### **Most common nondevice-related (≥3% in either group) adverse drug reactions.**

  **Summary, n (%)**           **Baseline dyskinesia subgroup**   
  ---------------------------- ---------------------------------- ------------------------
  Any ADR                      56 (50.9)                          65 (50.0)
                                                                  
  Serious                      31 (28.2)                          29 (22.3)
                                                                  
  Severe                       14 (12.7)                          22 (16.9)
                                                                  
  Discontinuation due to ADR   5 (4.5)                            12 (9.2)
                                                                  
  **Preferred term, n (%)**    **\<4 h/day (n = 110)**            **≥4 h/day (n = 130)**
                                                                  
  Weight decreased             6 (5.5)                            12 (9.2)
                                                                  
  Polyneuropathy               6 (5.5)                            5 (3.8)
                                                                  
  Hallucination                6 (5.5)                            2 (1.5)
                                                                  
  Abdominal pain               6 (5.5)                            2 (1.5)
                                                                  
  Dyskinesia                   3 (2.7)                            4 (3.1)
                                                                  
  Parkinsonism                 2 (1.8)                            5 (3.8)
                                                                  
  Psychotic disorder           1 (0.9)                            4 (3.1)
                                                                  
  Depression                   0 (0)                              4 (3.1)
                                                                  
  Fall                         0 (0)                              4 (3.1)

ADR: Adverse drug reaction.

Discussion {#S0016}
==========

In this posthoc analysis of the GLORIA study, LCIG-treated patients with advanced PD who had ≥4 h/day of dyskinesia at baseline had significant and sustained reductions in dyskinesia time, severity and associated pain over 24 months of treatment, despite an increase in levodopa-equivalent daily dose. These results align with the concept that changing the pattern of levodopa delivery from pulsatile to continuous is a critical factor in reducing pre-existing levodopa-induced dyskinesias \[[@B13]\]. Previous studies with continuous drug delivery schemes, both of levodopa with LCIG and apomorphine (subcutaneous), have likewise shown reductions in dyskinesia burden despite increases in LED \[[@B17]\]. Imaging data using raclopride positron emission tomography scan have indeed suggested sustained synaptic dopamine release with continuous intrajejunal levodopa infusion \[[@B20]\]. These data expand on previous reports of the effect of LCIG on dyskinesia in patients with advanced PD \[[@B18],[@B19]\], with a larger patient population observed over a longer period of time in the current study.

Patients with \<4 h/day of dyskinesia at baseline experienced increased duration of dyskinesia over the course of the study, but at the same time there was numerical improvement of dyskinesia severity. Pain associated with dyskinesia and QoL also improved indicating that increased dyskinesia duration was due to nontroublesome involuntary movements.

As expected, LCIG treatment led to a significant decrease in 'Off' time, regardless of baseline dyskinesia duration. Patients with ≥4 h/day of dyskinesia at baseline experienced significant improvements in QoL over 24 months of LCIG treatment; those with low dyskinesia burden at baseline did so through month 12. ADRs were consistent with the known safety profile of LCIG and were comparable between subgroups.

Although this open-label, noncontrolled registry is limited also by its posthoc nature, it provides a clearer understanding of the impact of continuous administration of levodopa on dyskinesia, which has not been extensively studied. Future prospective studies of the effect of LCIG on dyskinesia in patients with advanced PD are warranted. One such study (NCT02799381) is ongoing and is using the Unified Dyskinesia Rating Scale with the primary outcome being the effect of LCIG on dyskinesia in advanced PD patients.
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